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ABSTRACT
Recently, the EuropeanMedicines Agency approved the use of the
vasopressin V2 receptor antagonist tolvaptan to slow the progres-
sion of cyst development and renal insufﬁciency of autosomal
dominant polycystic kidney disease (ADPKD) in adult patients
with chronic kidney disease stages 1–3 at initiation of treatment
with evidence of rapidly progressing disease. In this paper, on
behalf of the ERA-EDTAWorking Groups of Inherited Kidney
Disorders and European Renal Best Practice, we aim to provide
guidance for making the decision as to which ADPKD patients
to treat with tolvaptan. The present position statement includes© The Author 2016. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com
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a series of recommendations resulting in a hierarchical decision
algorithm that encompasses a sequence of risk-factor assessments
in a descending order of reliability. By examining the best-
validated markers ﬁrst, we aim to identify ADPKD patients who
have documented rapid disease progression or are likely to have
rapid disease progression. We believe that this procedure offers
the best opportunity to select patients who aremost likely to bene-
ﬁt from tolvaptan, thus improving the beneﬁt-to-risk ratio and
cost-effectiveness of this treatment. It is important to emphasize
that the decision to initiate treatment requires the consideration
of many factors besides eligibility, such as contraindications, po-
tential adverse events, as well as patient motivation and lifestyle
factors, and requires shared decision-making with the patient.
Keywords: ADPKD, tolvaptan, vasopressin V2 receptor
antagonist
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common hereditary kidney disorder [1, 2], accounting for
∼10% of European patients on dialysis or living with a renal
transplant [3]. Approximately 70% of patients with ADPKD
progress to end-stage renal disease (ESRD) at a median age of
58 years [4]. ADPKD is genetically heterogeneous and is asso-
ciated with a high degree of inter- and intra-familial variability
in disease course. The 85% of patients with PKD1 mutations
typically display a more severe disease course, especially when
they have truncating mutations, with ESRD occurring 20 years
earlier than in the 15% of patients with PKD2 mutations [5].
ADPKD is characterized by the progressive development and
growth of numerous bilateral renal cysts, resulting in urine con-
centration defects, hypertension, acute and chronic pain, kidney
stones, haematuria, cyst and urinary tract infections, and, most
importantly, renal function loss [6, 7]. Cyst development and
growth usually start in utero and are continuous, but kidney
function is typically conserved until the age of 30–40 years. Com-
pensatory hyperﬁltration by glomeruli serving non-cystic tubules
maintains the glomerular ﬁltration rate (GFR) of affected pa-
tients within a normal range for prolonged periods of time [7, 8].
Until recently, no interventions were shown to slow the rate
of disease progression in ADPKD [9]. The treatment of
ADPKD has therefore been symptomatic, with the aim of redu-
cing morbidity and mortality associated with disease manifes-
tations [9]. This changed with the publication of the TEMPO
3:4 trial, which tested the efﬁcacy of the vasopressin V2 receptor
antagonist tolvaptan [10]. In this trial, 1445 patients with
ADPKD were randomized to receive either placebo or tolvap-
tan in a split-dose regimen of 45 mg in the morning and 15 mg
in the afternoon, uptitrated to 90/30 mg when tolerated. The
trial duration was 3 years, which is typical for trials investigating
renoprotective effects of medical interventions [11–14]. Per
protocol, all patients were advised to increase ﬂuid intake. In-
clusion criteria were age 18–50 years, an estimated creatinine
clearance (eCrCl) (Cockroft-Gault) ≥60 mL/min and a total
kidney volume (TKV) ≥750 mL. Study medication was discon-
tinued in 23% of tolvaptan- and 14% of placebo-treated
patients. The intention-to-treat analysis of this study showed
that tolvaptan slowed the rate of TKV growth (primary end-
point) by 49% from5.5 to 2.8%per year, and the rate of estimated
GFR (eGFR) loss on treatment (secondary endpoint) by 26%
from 3.70 to 2.72 mL/min/1.73 m2 per year during the median
observation period of 3 years [10]. Provided that this effect was
maintained, it would translate into every 4 years of treatment de-
laying the incidence of ESRD by approximately one additional
year. The renoprotective efﬁcacy of tolvaptan in ADPKD com-
pares well with the 15% reduction in eGFR decline (5.2 versus
4.4 mL/min/1.73 m2 per year) and 15% reduction in creatinine
clearance decline (6.5 versus 5.5 mL/min/1.73 m2 per year) in
the RENAAL and IDNT trials, respectively, which tested
angiotensin-2 receptor antagonists in patients with type 2 dia-
betes and kidney disease [13, 14], and with the 35% reduction
in decline in creatinine clearance in the study that tested
angiotensin-converting enzyme inhibition in patients with type
1 diabetes and kidney disease [11].Withdrawal from active treat-
ment in these trials was 47, 24 and 19%, respectively [11, 13, 14].
Traditionally, the primary endpoint in trials testing renopro-
tective effects of interventions has been the incidence of ESRD
or doubling of serum creatinine, which correlates to a 57%
reduction in eGFR. Of note, ADPKD is a relatively slowly pro-
gressive disease. In a population such as that of the TEMPO 3:4
trial, which was selected to have early-stage ADPKD (eCrCl
>60 mL/min), it cannot be expected that this endpoint will
occur within the typical duration of a renal trial. Adopting
this endpoint would therefore only pick up cases of acute
kidney injury and not be of help for studying the effect of inter-
ventions on progression of the disease itself. To stimulate pro-
gress in developing renoprotective agents, especially for studies
in early-stage chronic kidney disease (CKD) and diseases that
are relatively slow in progression, the nephrological community
has pleaded for the use of alternative endpoints for renal trials,
namely lesser declines in eGFR [15, 16]. Regulatory authorities
have accepted this proposal [17]. When studying the incidence
of a 25% reduction in eGFR [a priori deﬁned in the TEMPO 3:4
trial and accepted by the European Medicines Agency (EMA)],
there was a signiﬁcant 61% relative risk reduction with tolvap-
tan (number needed to treat to prevent one event was∼11) [10].
Based on the results of the TEMPO 3:4 trial, the EMA
approved in May 2015 the use of tolvaptan (JINARC®) for
ADPKD [18]. The regulatory authorities in Japan, Canada,
Korea and Switzerland recently also granted marketing author-
ization, whereas in the USA the Food and Drug Administration
asked in 2014 for additional efﬁcacy and safety data [19].
NEED FOR GUIDANCE ON IDENTIFYING
PATIENTS FOR TREATMENT
According to the EMA label, tolvaptan ‘is indicated to slow the
progression of cyst development and renal insufﬁciency of
ADPKD in adults with CKD stages 1–3 at initiation of treat-
ment with evidence of rapidly progressing disease’. This indica-
tion incorporates two issues that need clariﬁcation: ﬁrst, the
CKD stage and age that qualify patients for treatment, and
second, how to deﬁne ‘evidence of rapidly progressing disease’.
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To date, there have been no widely accepted clinical guide-
lines for the treatment of ADPKD. With tolvaptan having now
been granted marketing authorization in the EU, there is a need
for treatment guidance that is applicable to clinical practice. In
this paper, on behalf of the ERA-EDTAWorking Groups of
Inherited Kidney Disorders (WGIKD) and European Renal
Best Practice (ERBP), we aim to provide guidance for making
the decision as to which ADPKD patients to treat with tolvap-
tan. The present position statement includes a series of recom-
mendations, which result in a hierarchical decision algorithm
encompassing a sequence of risk-factor assessments in a des-
cending order of reliability. By examining the best-validated
markers ﬁrst, we aim to identify ADPKD patients with demon-
strated rapid disease progression or likely rapid disease progres-
sion, who may be considered for treatment with tolvaptan.
Patients who are identiﬁed as having possible rapid disease pro-
gression should not be started on treatment, but can be followed
to reassess the indication for start of treatment after 3–5 years.
In addition, this algorithm will help to screen out those who are
ineligible. It is important to emphasize that the decision to
initiate treatment requires the consideration of many factors
besides eligibility, such as contraindications, potential adverse
events, as well as patient motivation and lifestyle factors, and
requires shared decision-making with the patient.
CKD STAGE AND AGE AT THE INITIATION
OF TREATMENT
The EMA label for tolvaptan allows the treatment of patients
with CKD stages 1–3, i.e. with an eGFR of >30 mL/min/1.73 m2.
One of the inclusion criteria for the pivotal TEMPO3:4 trial was
a creatinine clearance as estimated with the Cockroft-Gault
equation ≥60 mL/min/1.73 m2 [10]. Due to tubular creatinine
secretion, creatinine clearance overestimates GFR by ∼20%
[20]. Consequently, the TEMPO 3:4 trial included a consider-
able number of ADPKD patients (n = 247; 17%) with an eGFR,
as determined by the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation, of <60 mL/min/1.73 m2. A
post hoc analysis indicated that in these patients, treatment efﬁ-
cacy was similar or even slightly better than in those with higher
eGFR [10]. However, the number of patients with CKD stage 3b,
i.e. an eGFR of 30–45 mL/min/1.73 m2, was small (n = 42; 3%).
The REPRISE study investigating the value of tolvaptan in 1300
patients with lower levels of eGFR (25–65 mL/min/1.73 m2) is
ongoing [21]. It is our opinion that until the results of this
study become available, information on the beneﬁt-to-risk
ratio of tolvaptan in patients with 30–45 mL/min/1.73 m2
(CKD stage 3b) is too limited to warrant treatment.
The UK National Institute for Health and Care Excellence
(NICE) recommends excluding patients with CKD stage 1
from treatment [22]. The exclusion of this subgroup is based
on a cost-effectiveness analysis that was performed using data
on the change in eGFR of patients participating in the
TEMPO 3:4 trial. These data were used to model lifetime risk
for ESRD in placebo- and tolvaptan-treated patients per CKD
stage. The effect of tolvaptan in decreasing the rate of change in
eGFR was 16, 29 and 31% in CKD stages 1, 2 and 3, respectively
[23]. These data seem to suggest that tolvaptan has less reno-
protective efﬁcacy in CKD stage 1. However, change in eGFR
is a less valid outcome measure to assess treatment effect in
early-stage ADPKD. As expected, patients with CKD stage 1
in the TEMPO 3:4 trial were younger. Because of the fact that
in ADPKD patients, eGFR can remain stable for a relatively
long time before progressing towards ESRD, it is difﬁcult to as-
sess the efﬁcacy of treatment on disease progression when using
change in eGFR as the outcome.When using change in TKV in-
stead, no lesser effect was observed in patients with CKD stage
1. The decreases in the rate of TKV growth on tolvaptan versus
placebo were 40, 60 and 40% in CKD stages 1, 2 and 3, respect-
ively [23]. Given these data, we believe that, at present, there are
no indications suggesting that tolvaptan is less effective in
delaying disease progression in young ADPKD patients with
CKD stage 1. However, it should be emphasized that the use of
tolvaptan in this patient category should be limited to those who
are likely to have rapidly progressing disease (see below).
According to the label of tolvaptan, all ADPKD patients
older than 18 years are eligible for treatment. However, we
believe that an age >50 years argues against initiation of this
drug, for two main reasons. First, the age inclusion range in
the TEMPO 3:4 trial was 18–50 years [10]. Consequently,
information on the beneﬁt-to-risk ratio of starting tolvaptan
in individuals older than 50 years is lacking. Second, ADPKD
progresses steadily over time and thus markers of disease sever-
ity and prognosis must be interpreted in conjunction with age.
In our opinion, ADPKDpatients with a relatively high eGFR for
their age group are unlikely to show rapid disease progression.
This would argue against treating patients aged >50 years who
still have an eGFR >45 mL/min/1.73 m2 (CKD stages 1–3a),
which is the minimum eGFR level for start of treatment, because
these patients have a high probability of slowly progressive disease.
Likewise, we also recommend not to treat patients aged 40–50
years who have an eGFR >60 mL/min/1.73 m2 (CKD stages 1
and 2), or patients 30–40 years who have an eGFR >90 mL/
min/1.73 m2 (CKD stage 1). Of course, this advice should be in-
terpreted with caution. The concept that biological rather than
chronological age is important is gaining increased attention in
medicine, and should also be considered in the context of these
recommendations. Thus, in individual cases, it may therefore be
prudent to base the assessment of whether or not to start treat-
ment also on a global risk proﬁle and to allow some ﬂexibility,
also taking into account patient motivation.
Recommendation 1.1: We suggest that tolvaptan can be pre-
scribed to adult ADPKD patients aged <50 years with CKD
stages 1–3a (eGFR >45 mL/min/1.73 m²) who have demon-
strated or who are likely to have rapidly progressing disease,
but that CKD stagemust be interpreted in conjunctionwith age.
Recommendation 1.2: We recommend not starting tolvap-
tan in patients aged 30–40 years with CKD stage 1 (eGFR
>90 mL/min/1.73 m²).
Recommendation 1.3: We recommend not starting tolvap-
tan in patients aged 40–50 years with CKD stages 1 or 2
(eGFR >60 mL/min/1.73 m²).
N
D
T
P
E
R
S
P
E
C
T
IV
E
S
R e c o m m e n d a t i o n s f o r t h e u s e o f t o l v a p t a n i n A D P K D 339
EVIDENCE OF RAPID DISEASE
PROGRESSION
General considerations
While the EMA does not state why the indication for tolvap-
tan use focuses on patients with rapidly progressing disease, it is
plausible that the beneﬁt-to-risk ratio is highest in such
patients. In contrast, patients who are slowly progressive
would receive long drug exposure for little or no beneﬁt.
However, no ofﬁcial recommendations are provided as to
who qualiﬁes as having ‘rapid disease progression’.
The main renal outcome of ADPKD is ESRD. The under-
lying premise to deﬁne rapidly progressing disease should
therefore, in our opinion, be progression to ESRD at an early
age. Unfortunately, there is no generally accepted deﬁnition
of early-onset ESRD in ADPKD. However, it seems logical to
deﬁne it as occurring before the average age for initiation of
renal replacement therapy (RRT) in ADPKD, which in Europe
is around 58 years of age [4].
A number of studies have tried to identify markers that can
predict rapid progression to ESRD in ADPKD [24, 25]. Figure 1
shows that awide variety of markers has been considered, but in
the present article we will concentrate on those that are better
validated (highlighted in Figure 1), bearing in mind that not all
factors are independent. The most important ones are kidney
function (as assessed by eGFR) and TKV.
As discussed above, measurement of change in eGFR during
early-stage ADPKD is of limited value for predicting disease
progression, because kidney function remains relatively stable
in the near-normal range for prolonged periods of time. In con-
trast, TKV typically increases from the very early stages of the
disease, usually long before renal function declines. Important-
ly, it was shown that change in TKV predicts a subsequent
change in eGFR [26], and that both the change in TKV over
time and baseline TKV predict a future rate of eGFR loss
[26–30].
Despite the clear association of TKV with renal function
decline in patient groups, there is signiﬁcant interindividual
variability, and renal function remains the more relevant
parameter for assessing disease severity and prognosis. For
instance, when a young ADPKD patient already has impaired
kidney function, without a possible cause other than
ADPKD, this indicates severe disease, independent of the
TKV. Likewise, when an older ADPKD patient has excellent
kidney function, this indicates mild disease, irrespective of
TKV. For this reason, the working groups have given more
weight to kidney function than to TKV in the design of the
treatment decision algorithm. It should be noted, however,
that speciﬁcally in young patients with CKD stage 1, kidney
functionmay be less sensitive for assessment of disease severity,
progression and prognosis (see below).
Documented change in GFR to deﬁne rapid disease
progression
GFR can be measured by calculating the clearance of exogen-
ous ﬁltrationmarkers, such as iothalamate or iohexol (mGFR), or
estimated using equations that incorporate serum concentrations
of endogenous ﬁltration markers and demographic variables
(eGFR). In the TEMPO 3:4 trial, serum creatinine level was
used to estimate GFR, applying the CKD-EPI equation [31].
This is in accordance with clinical practice. One study concluded
that, in ADPKD, equations used to estimate GFR may be less
reliable and may fail to detect changes in GFR over time [32].
Two other reports, however, showed that equations to estimate
GFR perform as well in ADPKD as in non-ADPKD CKD,
suggesting that these equations can be used in clinical care of
ADPKD patients [33, 34]. Although potentially valuable, meas-
urement of GFR using exogenousmarkers such as iothalamate or
iohexol will probably be limited to research settings and individ-
ual patients in whommuscle mass is obviously abnormal for age
and/or stature, because of the costs and limited availability of
such measurement methods.
F IGURE 1 : Markers used to assess prognosis in ADPKD. Shaded rectangles represent the best-validated markers (adapted from ref. [24]).
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Taking the natural variation in kidney function and meas-
urement error in creatinine determination into consideration,
small changes in eGFR may not reﬂect a true decline in renal
function, especially in early CKD stages when a relatively
small change in creatininemay result in a relatively large change
in eGFR. To conﬁdently identify ‘rapid disease progression’, the
rate of eGFR decline should therefore be supported by multiple
measurements. For this reason, this criterion should also be
deﬁned more strictly when historical data are available for
only a short period instead of a longer period. Consequently,
rapid disease progression may be identiﬁed by a conﬁrmed
eGFR decline ≥5 mL/min/1.73 m2 within 1 year, as suggested
by the KDIGO CKD Guideline [35], or by an average
annual eGFR decline of ≥2.5 mL/min/1.73 m2 over a period
of 5 years, which is comparable to the decline in eGFR in
class 1C patients of the Mayo classiﬁcation of ADPKD (see
below) [30].
It should be emphasized that, in ADPKD patients aged
<30 years with CKD stage 1, the observation of ‘no change in
eGFR’ in general is not considered a reliable predictor of slow
disease progression, because eGFR can remain fairly stable dur-
ing a prolonged period of time, whereas TKV increases steadily.
In such patients, changes in TKV and/or prediction models
should be used to assess or predict disease progression.
Importantly, when ‘evidence of rapid disease progression’ is
based on historical eGFR data, the decline in renal function
should be due to ADPKD and not related to other diseases,
medications or factors that may contribute reversibly or
irreversibly to the loss of renal function [e.g. diabetes mellitus,
non-steroidal anti-inﬂammatory drugs (NSAIDs), calcineurin
inhibitors, dehydration or contrast agents].
Recommendation 2: A conﬁrmed annual eGFR decline
≥5 mL/min/1.73 m2 in 1 year, and/or ≥2.5 mL/min/1.73
m2 per year over a period of 5 years, deﬁnes rapid progression.
Documented change in TKV to deﬁne disease progression
The increase in TKV corresponds to an increase in total cyst
volume, with exponential cyst enlargement being predictable
within individual patients [27, 28]. Methods that reliably and
accurately measure TKV have been developed using magnetic
resonance imaging (MRI) and computed tomography (CT).
Non-contrast MRI is preferable over CT on safety grounds, be-
cause it avoids radiation exposure [36]. It has been shown that,
when usingMRI, a change in TKV can reliably be detected after
a period of 6 months [37]. However, because of intra-individual
and intra-observer variability in TKV measured by MRI, we
advise assessing changes in TKV by repeated measurements,
especially when measurements are performed within a shorter
period of time (three or more times, preferably 6–12 months
apart). Although MRI measurement of TKV is accurate, and
also fast and easy to calculate when using the ellipsoid equation
to derive volume [36, 38], reimbursement policies and health-
care organizations may limit access to repeated MRI scans that
would allow TKV change to be measured. Measuring TKV se-
quentially using ultrasound may be more feasible, but this
technique is expected to be associated with too much variability
to reliably assess change in TKV, although this has not been
formally studied.
The working groups recommend adopting an established
TKV growth rate ≥5% per year, preferably measured by MRI,
for deﬁning rapid progression, which is likely to be a conserva-
tive threshold. This recommendation is supported by the 4.5%
growth rate threshold deﬁning Mayo class 1D patients (see
below) [30], and the average TKV growth in studies of
ADPKD patients with preserved renal function has been
measured as ∼5.0–5.5% per year [10, 27, 28, 37]. This criterion
of ≥5% TKV growth per year has also been advocated by the
Japanese regulatory authorities to deﬁne patients eligible
for treatment [39]. It is expected that only a few patients will
qualify for tolvaptan treatment based on this criterion of
historical change in TKV, because in clinical practice serial
MRI data will at present be available in only a limited number
of patients.
Recommendation 3: A TKV increase of >5% per year by
repeated measurements (preferably three or more, each at
least 6 months apart and by MRI), deﬁnes rapid progression.
Risk prediction using a single TKV value
Historical patient data on eGFR and/or TKV changes to
assist decision-making are not always available. In such cases,
prospective testing or risk prediction using data available at
the moment of assessment may be required.
The implications of large kidneys relate not only to disease
progression, but also to patient stature and age. A certain TKV
obviously has different meaning in patients with large versus
small stature, and similarly, different meaning in a young versus
an old subject. TKV should therefore be adjusted for height and
age. This concept was recently used by Irazabal et al. [30] to
develop a risk prediction tool. This risk prediction tool is
based on data from 590 ADPKD patients from the Mayo Clinic
Translational PKD Center with CT/MRI scans available and
three or more eGFR measurements over ≥6 months of follow-
up. Patients were classiﬁed radiologically as typical (class 1
patients, n = 538) or atypical (class 2 patients, n = 52), where
‘typical’means those with bilateral and diffuse cyst distribution
in both kidneys, with mild to severe replacement of kidney
tissue by cysts, and all cysts contributing similarly to TKV.
Patients with ‘atypical’ disease are those who do not fulﬁl
the criteria for ‘typical’ disease, and represent ∼5–10% of
ADPKD patients [30]. The ‘typical’ patients were randomly
partitioned into a development and an internal validation set,
and subclassiﬁed according to height-adjusted TKV (htTKV)
ranges for age (labelled 1A–1E). Thus, a model was developed
to classify ADPKD patients according to prognosis (Figure 2).
The proposed classiﬁcation was able to predict eGFR decline
and progression to ESRD in patients with typical ADPKD
over a broad range of CKD stages, even in patients at early stages
of the disease with preserved renal function. eGFR slopes over
time were signiﬁcantly different between subclasses and, except
for class 1A patients, different from those in healthy kidney
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donors. The frequency of ESRD at 10 years increased from
subclass 1A (2.4%) to 1E (66.9%) [30]. These ﬁndings were con-
ﬁrmed using data of another, independent cohort (CRISP)
[30]. Patients with Mayo classes 1C, 1D and 1E are thus pre-
dicted to have rapid disease progression and, accordingly,
would qualify for treatment in cases where historical data on
the rate of disease progression are lacking or not reliable, and
if patient age and eGFR are within the appropriate strata. A
calculator to estimate htTKV and classify patients with typical
ADPKD according to this classiﬁcation scheme is available
online [40]. Patients with atypical disease, in general, show
slowly progressive disease, which does not warrant treatment.
Using ultrasound tomeasure kidney volume is less expensive
and more accessible than MRI, but is hampered by operator-
dependency and low resolution [41]. Notwithstanding, the
CRISP studies suggested that a kidney length of 16.5 cm as
measured by ultrasound qualiﬁes patients younger than 45
years as having rapidly progressing disease [41]. A comparison
of ultrasound and MRI suggested that using either modality,
kidney length was able to predict disease progression. The
optimal cutoff for predicting the development of CKD stage
3a over a period of 8 years using ultrasound was a kidney length
of >16.5 cm (sensitivity 85% and speciﬁcity 92%) [41]. Import-
antly, in this study, ultrasound-derived kidney length was not
normalized for height or age of the patient, which, as reasoned
above, is likely to be important. Given these considerations, it is
our opinion that ultrasound-measured kidney length may be
useful to identify young ADPKD patients with clearly enlarged
or small kidneys for their height and age, in whomMRImay not
be required. In other cases, we suggest the use of MRI to accur-
ately measure TKV and predict the rate of disease progression.
Recommendation 4.1: We recommend the use of the Mayo
classiﬁcation of ADPKD that makes a distinction between
‘typical’ and ‘atypical’ morphology and adjusts TKV in
patients with ‘typical’morphology for age and height to deﬁne
ﬁve classes of patients according to prognosis (1A–1E).
Recommendation 4.2: We suggest that in ADPKD patients
with Mayo classes 1C–1E disease (corresponding to a
predicted eGFR decrease ≥2.5 mL/min/1.73 m² per year),
rapid disease progression is likely.
Recommendation 4.3: We suggest that in patients with
atypical morphology of ADPKD, as described in the Mayo
classiﬁcation, rapid disease progression is unlikely.
Recommendation 4.4: We suggest that in a patient with age
<45 years and a kidney length of >16.5 cm as assessed by
ultrasound, rapid disease progression is likely.
Risk prediction using genetic and clinical factors
As previously described, in ADPKD the genotype provides
prognostic information. On average, patients with PKD1
mutations, especially truncating PKD1 mutations, show a
signiﬁcantly faster progression to ESRD than those with
PKD2 mutations [5]. A cross-sectional study of 1341 patients
from the Genkyst cohort has been used to establish the
F IGURE 2 : The Mayo classiﬁcation for prediction of disease progression in ADPKD by htTKV and age. In general, class 1C, 1D and 1E patients
will have rapid disease progression and qualify for treatment (derived from ref. [27]). Limits are deﬁned based on estimated TKV growth rates of
1.5, 3.0, 4.5 and 6.0% per year. Estimated slopes of eGFR loss by subclass (1A–1E) are −0.1, −1.2, −2.5, −3.4 and −4.6 mL/min/1.73 m2 per year,
respectively, with no signiﬁcant differences betweenmen and women. The incidence of ESRD at 10 years increased by subclass (1A–1E), being 2.4,
11.0, 37.8, 47.1 and 66.9%, respectively [30].
N
D
T
P
E
R
S
P
E
C
T
IV
E
S
342 R.T. Gansevoort et al.
‘PRO-PKD’ risk-scoring system on the basis of PKD mutation
as well as clinical parameters [42]. Using multivariate survival
analysis to identify variables signiﬁcantly associated with age at
ESRD onset, a scoring system was developed that gives a value
ranging from 0 to 9. This scoring system is shown in detail in
Table 1. A score of ≤3 excludes progression to ESRD before the
age of 60 years with a negative predictive value of 81.4%, and a
score of >6 predicts ESRD onset before the age of 60 years with a
positive predictive value of 90.9%. For those with an intermedi-
ate score (4–6 points), the prognosis is unclear [42]. The limited
availability and the signiﬁcant costs of genetic analysis in
ADPKD still represent barriers to the incorporation of this ana-
lysis into standard clinical practice. While genetic testing is at
present advised in only a limited number of situations and is
certainly not mandatory for deﬁning a treatment indication,
it may gain importance in the future, because of the potential
therapeutic consequences. In those cases in which information
on speciﬁc PKD mutations is available from routine care, this
information, in conjunction with clinical ﬁndings and symp-
toms, may help to predict prognosis using the PRO-PKD score.
Recommendation 5: We suggest that in patients with a
truncating PKD1 mutation in conjunction with early onset
of clinical symptoms, consistent with a PRO-PKD score of
>6, rapid disease progression is likely.
Risk prediction using family history
Although intra-familial variability occurs with respect to the
age at start of RRT [43], a detailed family history can provide
important information for risk prediction. It has been shown
that an ADPKD patient with two ﬁrst-degree family members
reaching ESRD before the age of 58 years has a high sensitivity
(75%) and speciﬁcity (100%) for being affected by a PKD1mu-
tation [44]. This suggests that a patient, who does not qualify for
the initiation of treatment by the recommendations above, but
has a family history of most affected members reaching ESRD
before the age of 58 years, may be at risk for rapid disease
progression. In such patients, the markers that may indicate
treatment initiation should be reassessed every 3–5 years.
Recommendation 6: We suggest patients with a family his-
tory of ESRD before age 58 years be reassessed for rapid dis-
ease progression on a 3–5 yearly basis.
AN ALGORITHM TO ASSESS ELIGIBIL ITY
FOR TOLVAPTAN TREATMENT IN ADPKD
A hierarchical algorithm may be of help to assess whether
ADPKD in patients is rapidly progressing or likely to be rapidly
progressing, taking into account documented kidney function
(eGFR) decline, documented (ht)TKV growth and other clinical
factors as discussed above (Figure 3). This algorithm starts with
the most reliable markers of progression, moving on to less de-
ﬁnitive indicators in cases where historical data on eGFR decline
or TKV growth are not available or not reliable. Given the con-
straints on patient testing,we believe that this procedure offers the
best opportunity of identifying patients with rapidly progressing
disease who are most likely to beneﬁt from therapy, thus improv-
ing the beneﬁt-to-risk ratio and cost-effectiveness of treatment.
Initiating treatment with tolvaptan should be considered for
patients having demonstrated rapid progression, orwho are likely
to have rapid progression. For patients with possible rapid pro-
gression, additional information should be sought before treat-
ment is initiated, for example by ad hoc assessment of htTKV
or genotype, or subsequent monitoring for changes in eGFR
and/or TKV. Patients with possible rapid progression should be
re-evaluated for treatment every 3–5 years, or earlier if new, rele-
vant patient data or better prediction models become available.
Recommendation 7:We suggest using a hierarchical decision
algorithm to assess whether ADPKD patients are rapid
progressors or likely to be rapid progressors, and accordingly
may qualify for treatment.
CONTRAINDICATIONS , SPECIAL WARNINGS
AND PRECAUTIONS
Besides a careful assessment of which patients may beneﬁt most
from tolvaptan, other considerations should be taken into
account when considering prescribing this drug, including
the contraindications to its use in ADPKD. These are summar-
ized in Table 2 [45].
A special warning relates to potential liver toxicity. During
tolvaptan use, an increased incidence of liver function test
abnormalities was observed. An alanine transaminase (ALT)
and aspartate transaminase (AST) level at least three times
the upper limit of normal (ULN) was observed in 4.4 and
3.1% of tolvaptan-treated patients, respectively, compared
with 1.0 and 0.8% of placebo-treated patients [10]. In addition,
three ADPKD patients showed a 2-fold rise in bilirubin along-
side a 3-fold rise in transaminases (so-called Hy’s Law cases)
[45, 46]. The simultaneous increase in transaminases and bili-
rubin is considered as a high-risk signal, since the hepatic cap-
acity to excrete bilirubin is high and any impairment of this
capacity in conjunction with an increase in transaminases is
considered to be associated with the risk for severe hepatic
side effects [47]. Nearly all cases of liver function test abnormal-
ities occurred during the ﬁrst 18 months of treatment [46].
Based on the incidence of the Hy’s Law cases, it has been esti-
mated that per 10 000 treated patients potentially three cases of
Table 1. The PRO-PKD score to assess prognosis in ADPKD (derived from
ref. [42])
Being male: 1 point
Hypertension before 35 years of age: 2 points
First urological event (macroscopic haematuria, ﬂank pain or cyst
infection) before 35 years of age: 2 points
PKD2 mutation: 0 points
Non-truncating PKD1 mutation: 2 points
Truncating PKD1 mutation: 4 points
A score of≤3 excludes progression to ESRD before the age of 60 years with
a negative predictive value of 81.4%.
A score of >6 predicts rapid disease progression with ESRD onset before
the age of 60 years with a positive predictive value of 90.9%.
For thosewith an intermediate score (4–6 points), the prognosis is unclear.
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fatal liver toxicity could occur [48]. The EMA has therefore ad-
vised monitoring of liver function tests on a monthly basis dur-
ing the ﬁrst 18 months of treatment and 3 monthly thereafter
[18]. The label of tolvaptan provides rules regarding when to
stop tolvaptan treatment in case of de novo liver function test
abnormalities, which are summarized in Table 2 [45]. In all
F IGURE 3 : Algorithm to assess indications for initiation of treatment in ADPKD. The EMA label for tolvaptan states that this drug is indicated
for ‘ADPKD patients with CKD stages 1–3 and evidence of rapid disease progression at initiation of treatment’. A deﬁnition of ‘evidence of rapid
disease progression’ is not provided. The diagram aims to deﬁne rapid progression, and thus allow the identiﬁcation of patients eligible for
treatment. It is based on the assumption that GFR for age, or historical changes in GFR, provides more information on disease progression than
changes in TKVor risk prediction scores based on (ht)TKVor PKD genemutation analysis in conjunction with clinical signs. Patients identiﬁed as
showing ‘rapid progression’ or ‘likely rapid progression’may be considered for treatment with tolvaptan. Patients with ‘possible rapid progression’
should be re-evaluated during follow-up visits. Besides assessing the indication for treatment, contraindications to and special warnings for tol-
vaptan use in ADPKD should be considered (see Table 2). Notes to the decision algorithm. (a) In our opinion, the indication ‘CKD stages 1–3 at
initiation of treatment’ is not sufﬁciently speciﬁc as eGFR should be indexed for age. ADPKD patients with a high eGFR for age are unlikely to show
rapid disease progression. There is currently no published evidence for the effect of tolvaptan in patients below the age of 18 or above the age of 50
years. (b) eGFR may vary over time in individual patients, especially when close to the normal range. To conﬁdently deﬁne ‘rapid disease pro-
gression’, the rate of eGFR decline should be supported by multiple measurements that reliably indicate a rate of decline in eGFR. For this reason,
this criterion should also be deﬁned more strictly when historical data are available for only a short period compared with when available for a
longer period. (c) When ‘evidence of rapid disease progression’ is based on historical eGFR data, the decline in renal function should be due to
ADPKD and not related to other diseases, medications or factors that may contribute (reversibly or irreversibly) to a decline in renal function (e.g.
diabetes mellitus, NSAIDs, calcineurin inhibitors, dehydration or contrast agents). (d) The criterion decline in eGFR≥5 mL/min/1.73 m2 in 1 year
is adopted from the KDIGO CKD Guideline [35]. (e) The criterion decline in eGFR ≥2.5 mL/min/1.73 m2 per year over a period of 5 years is
comparable to class 1C patients in the Mayo classiﬁcation of ADPKD [30]. (f ) In young ADPKD patients with CKD stage 1, the observation of ‘no
change in eGFR’ in general is not considered a sensitive marker of slow disease progression, as eGFR often remains fairly stable during a prolonged
period of time, whereas TKV increases steadily, suggesting disease progression. In such patients, changes in TKV and/or prediction models should
be applied to assess historical or predicted disease progression. (g) The criterion of increase in TKV ≥5% per year is likely to be conservative. It is
based on the threshold deﬁning theMayo class 1C patients [30]. This criterion has also been advocated by the Japanese regulatory authorities [39].
The average rate of TKV growth in placebo-treated patients in the TEMPO 3:4 trial was 5.5% per year [10]. (h) The ellipsoid equation estimates
TKV reliably when compared with classical volumetry [30, 34]. (i) TheMayo classiﬁcation of ADPKD is based on height-adjusted TKV indexed for
age. It predicts that patients with class 1C, 1D and 1E have more rapid disease progression [30]. A kidney length ≥16.5 cm, as assessed by
ultrasound (or MRI), can be used in patients younger than 45 years to indicate a high likelihood of rapid disease progression [41]. ( j) The
PRO-PKD score suggests that patients with a truncating PKD1 mutation and early onset of clinical signs (i.e. hypertension, macroscopic
haematuria, cyst infection or ﬂank pain before the age of 35 years) have rapid disease progression with start of RRT at a relatively young age [42]. (k)
Although there is signiﬁcant variability in the age of reaching ESRD within families that share the same mutation, clinical experience as well as
observational studies have shown that a detailed family history can provide important information for risk prediction [44].
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ADPKD patients, liver function test abnormalities were revers-
ible after drug cessation and as yet no case of fatal liver toxicity
has occurred [46].
There are special precautions for the use of tolvaptan in
patients with gout, those using diuretics, patients with diabetes
mellitus and patients with possible bladder dysfunction/
voiding problems. In the TEMPO 3:4 trial, a higher incidence
of gout was observed in patients treated with tolvaptan when
compared with placebo [10]. In this trial, physicians were
advised not to prescribe diuretics, out of fear that electrolyte
disturbances might occur. Whether this is a real concern or
not is difﬁcult to assess at present because due to this advice
the concomitant use of tolvaptan and diuretics has been low.
Until more data become available, it seems prudent to restrict
the concomitant use of diuretics. It has been suggested that tol-
vaptanmay cause hyperglycaemia. V2 receptor blockade results
in a slight compensatory increase in circulating arginine vaso-
pressin [49], which in theory may stimulate hepatic glucose
production via increased activation of V1a receptors [50]. In
line with this, prior placebo-controlled trials in hyponatraemia
suggested a higher incidence of hyperglycaemia in tolvaptan-
treated subjects compared with placebo. In the TEMPO 3:4
trial, poorly controlled diabetes mellitus (i.e. fasting glucose
>126 mg/dL or glycosuria by dipstick) was an exclusion criter-
ion, but in this trial the incidence of hyperglycaemia as
treatment-related adverse event was actually lower with
Table 2. Contraindications, special warnings and precautions for the use of tolvaptan in ADPKD as derived from the EMA-approved label [45]
Contraindications
•Hypersensitivity to the active substance or to any of the excipients
• Elevated liver enzymes and/or signs or symptoms of liver injury
prior to initiation of treatment that meet the requirements for
permanent discontinuation of tolvaptan
• Volume depletion
• Hypernatraemia
• Patients who cannot perceive or respond to thirst
• Pregnancy
• Breast-feeding
Special warnings and precautions
Idiosyncratic hepatic toxicity Tolvaptan has been associated with idiosyncratic elevations of blood alanine and aspartate
aminotransferases (ALT and AST) with infrequent cases of concomitant elevations in
bilirubin-total (BT). While these concomitant elevations were reversible with prompt
discontinuation of tolvaptan, they represent a potential for signiﬁcant liver injury.
Guidelines to stop tolvaptan include:
ALT or AST >8 times ULN
ALT or AST >5 times ULN for >2 weeks
ALT or AST >3 times ULN and BT >2 times ULN
ALT or AST >3 times ULN with persistent symptoms of hepatic injury
Access to water Tolvaptan induces aquaresis andmay cause adverse reactions related to water loss, such as
thirst, polyuria, nocturia and pollakiuria. Therefore, patients must have access to water (or
other aqueous ﬂuids) and be able to drink sufﬁcient amounts of these ﬂuids to avoid
dehydration.
Dehydration Special care must be taken in patients having diseases that impair appropriate ﬂuid intake
or who are at an increased risk of water loss, e.g. in case of vomiting or diarrhoea. Such
patients should interrupt or reduce the dose of tolvaptan and increase ﬂuid intake.
Urine outﬂow obstruction Urinary output must be secured. Patients with partial obstruction of urinary outﬂow, for
example patients with prostatic hypertrophy or impairment of micturition, have an
increased risk of developing acute retention.
Fluid and electrolyte disturbances The aquaretic effect of tolvaptan may cause dehydration and increases in serum sodium.
Therefore, serum creatinine and electrolytes have to be assessed prior to and after starting
tolvaptan to monitor for dehydration.
Anaphylaxis Anaphylaxis has been reported very rarely following administration of tolvaptan. In case
of anaphylaxis, administration of tolvaptan must be discontinued immediately and
appropriate therapy initiated.
Diabetes mellitus It has been suggested that tolvaptan may cause hyperglycaemia. Therefore, diabetic
patients treated with tolvaptan must be managed cautiously.
Uric acid increases Decreased uric acid clearance by the kidney is a known effect of tolvaptan. Adverse
reactions of gout were reported more frequently in tolvaptan-treated patients (2.9%) than
in patients receiving placebo (1.4%).
Effect on GFR A reversible reduction in GFR has been observed at the initiation of tolvaptan treatment.
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tolvaptan compared with placebo (0.6 versus 2.1%) [10]. Until
further data become available, diabetic patients treated with tol-
vaptan should be managed cautiously. Because of the high 24-h
urine outputs that result from using tolvaptan, care should
be taken not to prescribe this drug to patients with possible
bladder dysfunction or voiding problems in order to prevent
post-renal obstruction and consequent renal damage. A careful
urological history should therefore be taken in patients who are
considered for treatment.
Issues to be discussed with patients when considering pre-
scribing tolvaptan include the mechanism of drug action, ex-
pected adverse events and need for lifestyle modiﬁcations.
Blocking the vasopressin V2 receptor by tolvaptan induces a
strong dose-dependent aquaretic response, leading to an aver-
age 24-h urine volume of 5–6 L on the 90/30 mg dose [49].
Consequently, patients can experience thirst, dry mouth, poly-
uria and nycturia with disturbed night rest. In general, ADPKD
patients are highly motivated to start disease-modifying treat-
ment, because of personal experience with family members en-
countering complications associated with RRT. In line with
this, only 7.4% of tolvaptan-treated patients discontinued treat-
ment in the TEMPO 3:4 trial due to an aquaresis-related ad-
verse event. Most discontinuations because of aquaresis
occurred in the ﬁrst 3months of treatment [10]. Patients should
be advised to stop tolvaptan immediately in case of impending
dehydration, for instance in case of vomiting, diarrhoea or ex-
cessive sweating. Patients should be counselled on recommen-
dations for adequate ﬂuid intake to maintain water homeostasis
and avoid reﬂex vasopressin increases. They should be advised
to drink sufﬁcient water to prevent thirst throughout the day-
time period and an additional 1–2 cups of water before bedtime.
Patients may require considerable assistance in order tomanage
the aquaretic side effects of tolvaptan. Screening patients for the
likelihood of successful adherence, educating them on the aqua-
retic side effects before initiating tolvaptan and providing guid-
ance on necessary lifestyle adjustment is critical.
Given these considerations, tolvaptan treatment should be
initiated and monitored under the supervision of physicians
with expertise in managing ADPKD and a full understanding
of the risks of tolvaptan therapy, including liver toxicity, and
monitoring requirements. It should also be emphasized that
treatment with tolvaptan should not replace or offset current
medical management of ADPKD.
Recommendation 8.1:We recommend discussing adverse ef-
fects and impact on lifestyle with patients when considering
starting tolvaptan.
Recommendation 8.2: We recommend taking into account
contraindications and adverse effects such as hepatic toxicity
and other precautions as listed in Table 2 when considering
starting tolvaptan.
Recommendation 8.3:We recommend that prescription and
documentation of safety monitoring of tolvaptan is per-
formed under supervision of physicians with expertise in
managing ADPKD.
INITIATION, TITRATION AND
MAINTENANCE OF TREATMENT
Importantly, initiation of tolvaptan is associated with an acute
decrease in eGFR [49, 51]. After 3 weeks of treatment with a
total daily dose of 120 mg, a fall in GFR was noted ranging
from −0.7 to −7.8 mL/min/1.73 m2, depending on baseline
GFR [49]. This acute fall in GFR was reversible after treatment
withdrawal, similar to what is observed when using renin–
angiotensin–aldosterone system (RAAS) inhibitors. Physicians
should be aware of the initial acute and reversible GFR decrease
upon treatment initiation. As patients approach ESRD, tolvap-
tan should be discontinued in order to allow GFR to improve,
which may postpone the start of RRT.
In non-ADPKD CKD, the efﬁcacy of renoprotective treat-
ments can often be assessed in the short term by investigating
the effect on surrogate markers of efﬁcacy, such as blood pres-
sure and proteinuria. For instance, in patients with IgA nephro-
pathy, if proteinuria is not lowered sufﬁciently by agents
inhibiting the RAAS, treatment is deemed to be suboptimal.
These agents are then uptitrated, or other medication is
added [52]. Unfortunately, as yet there are no established short-
term markers of tolvaptan treatment efﬁcacy in ADPKD. The
dose of tolvaptan should therefore be prescribed as used in
the clinical trial that demonstrated treatment efﬁcacy, i.e. start-
ing tolvaptan at 45 mg in the morning and 15 mg in the after-
noon, to be uptitrated, when tolerated, to 60/30 and 90/30 mg,
respectively. In the TEMPO 3:4 trial, 23% of patients withdrew
from therapy during the 3 years of the trial. The remaining pa-
tients used an average total daily dose of 95 mg tolvaptan. Of
the patients who completed the trial, 55% took the high dose
(a total daily dose of 120 mg), whereas 21 and 24% took the
middle dose (90 mg) and low dose (60 mg), respectively [10].
In the TEMPO 3:4 trial, the effect of tolvaptan treatment on
the rate of TKV growth was larger during the ﬁrst year than dur-
ing the second and third years of treatment [20]. It has been
shown that tolvaptan induces an acute effect on TKV that is ob-
served after 1 week of treatment and that is reversible after treat-
ment cessation [49, 51]. This acute effect is assumed to be related
to a rapid decrease in cystic ﬂuid secretion [51], while later effects
on TKV growth rate appear to be more sustained [23]. The re-
sults of the TEMPO 3:4 trial do not indicate diminishing treat-
ment efﬁcacy with respect to the rate of change in eGFR during
the 3 years of the trial. In line with the assessment report by the
EMA, the working groups consider it rational to continue treat-
ment beyond 3 years, unless long-term treatment data in the un-
controlled open-label extension study that followed the TEMPO
3:4 trial suggest otherwise [21]. This study is ongoing.
Recommendation 9.1: We suggest tolvaptan treatment to be
started with a dose of 45 mg in the morning and 15 mg in the
evening.
Recommendation 9.2:We suggest uptitrating the dose of tol-
vaptan to 60/30 and 90/30 mg when tolerated.
Recommendation 9.3: We suggest tolvaptan treatment to be
discontinued when patients approach ESRD.
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CONCLUSIONS
Tolvaptan is the ﬁrst pharmaceutical treatment approved to
slow disease progression in ADPKD. Given the side effect pro-
ﬁle of this drug, and for cost reasons, it is necessary to identify
those patients who are most likely to beneﬁt from this drug. To
achieve this, we have proposed a hierarchical decision algorithm
to assess whether treatment is warranted, and deﬁned recom-
mendations for the safe use of tolvaptan in ADPKD.
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